肿瘤药学2018，Vol.8Issue(2)：258-262,5.DOI:10.3969/j.issn.2095-1264.2018.02.31
艾拉光动力联合咪喹莫特对基底细胞癌患者免疫指标的影响
The Effects of Ella Light Power Combined with Imiquimod Cream on Basal Cell Carcinoma
康康 1韩明辉 2丛明 1陈思 3张晓云 1张晶1
作者信息
- 1. 唐山工人医院 皮肤科,河北 唐山,063000
- 2. 河北医科大学第四医院 护理部,河北 石家庄,050000
- 3. 唐山工人医院 神经外科,河北 唐山,063000
- 折叠
摘要
Abstract
Objective To study the influence of Ella light power combined with imiquimod cream in treatment of basal cell carcinoma patients and its effects on immune indexes. Methods During February 2014 to January 2015, 72 basal cell carcinoma patients in our hos-pital were divided into observation group and control group by random, 36 cases in each group. The control group was given 635 nm Ella light power shining once a week and last for 4 weeks, the power was 300 MW, gross energy was 100 MJ·cm-2and the shining time was ac-cording the illuminance area of patients. The treatment for the observation group was based on the foundation of the control group, plus 5% imiquimod cream covering on the lesion skin. Before and after treatment, the immune indexes changes of the two groups were compared, the clinical efficacy, cosmetic effect and adverse reactions of the two groups were evaluated after treatment. Results The levels of CD3+, CD4+and NK cells and CD4/CD8 were significantly higher in the observation group than in the control group, while that of CD8+were significantly lower in the observation group than in the control group (P<0.05). In the observation group, total efficacy was significantly higher than in the control group (P<0.05). Moreover, the cosmetic effect was significantly better in observation group than in control group (P<0.05). Conclu-sion Ella light power combined with imiquimod cream can obviously safely improve the T cell subsets and NK cells, clinical curative effect as well as cosmetic effect of basal cell carcinoma patients.关键词
艾拉光动力/咪喹莫特/基底细胞癌/免疫指标Key words
Ella light power/Imiquimod cream/Basal cell carcinoma/Immune indexes分类
医药卫生引用本文复制引用
康康,韩明辉,丛明,陈思,张晓云,张晶..艾拉光动力联合咪喹莫特对基底细胞癌患者免疫指标的影响[J].肿瘤药学,2018,8(2):258-262,5.
